2022
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates
2020
Artificial intelligence in medical imaging: A radiomic guide to precision phenotyping of cardiovascular disease
Oikonomou EK, Siddique M, Antoniades C. Artificial intelligence in medical imaging: A radiomic guide to precision phenotyping of cardiovascular disease. Cardiovascular Research 2020, 116: 2040-2054. PMID: 32090243, PMCID: PMC7585409, DOI: 10.1093/cvr/cvaa021.Peer-Reviewed Original ResearchConceptsCardiac computed tomographyNon-invasive imagingCardiovascular imagingCardiovascular diseaseNon-invasive cardiovascular imagingCardiac CTCardiovascular risk stratificationFirst-line optionImportant clinical implicationsRisk stratificationUnstable patientsClinical careComputed tomographyCurrent evidenceClinical implicationsCardiac imagingRadiomics approachPatientsRadiomics methodTissue biologyCardiovascular diagnosticsDiseaseFuture studiesImagingPhenotyping